Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pVAX plasmid DNA (specifically the pVAX1 plasmid vector) is an empty, non-antigen-encoding bacterial plasmid DNA construct used as a control or placebo comparator in clinical and veterinary trials. Developed under the auspices of the Queensland Institute of Medical Research (QIMR) and collaborating institutions, it has been evaluated in a Phase 3 trial in China as a control vaccine within an integrated schistosomiasis control program targeting *Schistosoma japonicum* transmission in bovines (water buffalo and cattle). The plasmid serves as the backbone vector for active DNA vaccines (such as SjCTPI-Hsp70 and SjC23-Hsp70) but is administered in its empty form to establish baseline immune responses and evaluate vaccine efficacy. It is typically manufactured to GLP standards by contract manufacturers like Aldevron.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pVAX plasmid DNA.